Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
167 hedge funds and large institutions have $2.91B invested in Intercept Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 65 increasing their positions, 48 reducing their positions, and 24 closing their positions.
43% more call options, than puts
Call options by funds: $206M | Put options by funds: $144M
35% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 48
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
21% more capital invested
Capital invested by funds: $2.41B → $2.91B (+$504M)
4% more funds holding
Funds holding: 160 → 167 (+7)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$73.1M |
| 2 |
CG
Carmignac Gestion
Paris,
France
|
+$47.7M |
| 3 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
+$39.1M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$23.3M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$27.8M |
| 2 |
PC
PointState Capital
New York
|
-$19.9M |
| 3 |
Millennium Management
New York
|
-$19.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.9M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$8.38M |
ICPT Hedge Fund Activity: Q2 2016 in Review
167 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2016, worth a combined $2.91B — up 21% from $2.41B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ICPT positions and 24 closed out — a net gain of 8 holders — while 65 added to existing stakes and 48 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $73.1M. The largest seller was Sectoral Asset Management, cutting an estimated $27.8M.
- 167 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2016, up from 160 in Q1 2016.
- Funds reported $2.91B of Intercept Pharmaceuticals, Inc. stock for Q2 2016, up 21% quarter-over-quarter.
- 32 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2016 and 24 closed out, a net change of +8 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2016 was JP Morgan Chase, an estimated $73.1M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q2 2016 was Sectoral Asset Management, an estimated $27.8M sold.
Based on aggregated 13F filings for Q2 2016.